Category Archives: Embryonic Stem Cells


Georgetown student takes Islamic bioethics research at QF to Washington and wins – Gulf Times

An academic paper analysing the Muslim perspective on the controversial use of stem cell research has won Amna al-Essa, a Georgetown University in Qatar (GU-Q) student, second place in the Bioethics Research Showcase sponsored by the Kennedy Institute of Ethics in Washington, DC, one of the oldest academic ethics centres in the world.Amnas winning entry was judged by an interdisciplinary panel of judges and announced during a virtual awards ceremony.In the paper, she explores the background behind the Islamic rulings guiding the use and limitation of embryonic stem cells in the medical sciences, a field of research that holds great promise for the treatment of degenerative conditions and the understanding of human development.The medical technology uses cells from human embryos which has raised a host of ethical concerns and debates across cultures and countries.Muslim countries also face these debates, explained Amna, but often lack the needed guidance of a religious authority ruling.There is a pressing need to address continuing ethical concerns and questions that arise from societal, cultural and religious perspectives on issues that transgress into matters of prohibitions and permissibility in Islam.She was encouraged to submit her paper for competition by the instructor of her Islam, Culture and Bioethics course, associate research professor Dr Ayman Shabana.He is also the director of the Islamic Bioethics Project at GU-Q, which has been supported by three consecutive grants from Qatar National Research Funds National Priorities Research Programme.Being at GU-Q has definitely deepened my interest in the connections between Islam and bioethics. We are offered this great opportunity to be exposed to multiple fields and wider disciplines, like theology, philosophy and politics. This opportunity has allowed us to cultivate our own selves and knowledge based on our personal interests across different fields.An International Politics major student at GU-Q, a Qatar Foundation (QF) partner institution, Amna said it was during her pursuit of the Theology minor that she became interested in bioethics.I have always had a passion for science and medicine, which is why I decided to pursue them within the realm of liberal arts. Studying theology at Georgetown has widened my horizons to think about issues in the medical field and to consider how contemporary religious beliefs and practices deal with those issues.The Showcase is a jurieddigital exhibition of under-graduate research in a varietyof categories and disciplineson the ethics of health,the environment and thebioethics of emerging technologies.The virtual award ceremony as well as Amnas winning paper are available for viewing on the Kennedy Institute of Ethics website.

Read more from the original source:
Georgetown student takes Islamic bioethics research at QF to Washington and wins - Gulf Times

Dose-dependent functions of SWI/SNF BAF in permitting and inhibiting cell proliferation in vivo – Science Advances

INTRODUCTION

During development and tissue homeostasis, proliferating stem and progenitor cells ultimately give rise to daughter cells that acquire specialized functions. The terminal differentiation of such cells coincides with a permanent withdrawal from the cell division cycle. This cell cycle arrest is achieved by a combination of cell cycle regulators that include the retinoblastoma tumor suppressor (Rb) protein family of transcriptional corepressors, cyclin-dependent kinase (CDK)inhibitory proteins (CKIs) that bind and block CDKs, and E3 ubiquitin ligases such as the anaphase-promoting complex in association with the coactivator Cdh1/FZR1 (APC/C-FZR1) that promote protein degradation (1). In addition to these general regulators of the cell cycle, lineage-specific transcription factors and chromatin regulators coordinate the arrest of cell division with terminal differentiation. In particular, SWI/SNF (switch/sucrose nonfermenting) chromatin remodeling complexes have been found to play an important role in this process (24).

The multisubunit SWI/SNF chromatin remodeling complexes were initially identified as positive regulators of gene expression in yeast [for review, see (5)]. Independent studies in Drosophila identified SWI/SNF components as antagonists of Polycomb-mediated transcriptional repression, with homology searches revealing evolutionary conservation in mammals. Extensive biochemical characterizations support that multiple SWI/SNF subcomplexes are modularly assembled from a variety of different subunits. These SWI/SNF complexes contain an adenosine triphosphatase (ATPase) core subunit and use the energy generated by ATP hydrolysis to alter nucleosome occupancy at gene regulatory regions, to evict Polycomb-repressor complexes, and to participate in additional cellular processes such as DNA repair (68). SWI/SNF complexes can be divided into BRG1/BRM-associated factor (BAF) and Polybromo-associated BAF (PBAF) variants. These complexes consist of one of two mutually exclusive ATPase subunits (BRM/SMARCA2 or BRG1/SMARCA4), additional highly conserved core subunits (SNF5/SMARCB1, BAF155/SMARCC1, and BAF170/SMARCC2), an array of variable accessory subunits, and BAF- or PBAF-specific variant subunits (ARID1A/B, or ARID2, PBRM1, and BRD7, respectively) (9) (Fig. 1, A and B). While sophisticated in vitro studies have described the nature and function of SWI/SNF complexes at a biochemical level, in vivo characterizations of SWI/SNF complex functions and interactions with Polycomb group (PcG) proteins have been limited.

(A) Schematic representation of the two conserved SWI/SNF subcomplexes (using C. elegans nomenclature). (B) Table of C. elegans and mammalian homolog names for SWI/SNF subunits. The SWI/SNF complex consists of core subunits (green), accessory (blue), and BAF- (purple) and PBAF-specific (orange) signature subunits. (C) Lineage of the C. elegans mesoblast (M). The M cell is born during early embryogenesis and initiates proliferation halfway through the first larval stage (L1), forming 14 striated muscle cells (BWM), two scavenger cells [coelomocytes (CC)], and two ventral muscle precursor cells [sex myoblasts (SM)]. The SMs remain quiescent and migrate anteriorly to the vulva, resuming proliferation late in the third larval stage (L3), and differentiate to form 16 muscle cells required for egg laying. (D) Design of the lineage-tracing reporter, single-copy integrated into the C. elegans genome. A universal promoter (Peft-3) drives expression of tagBFP2 flanked by two LoxP sites and followed by the let-858 untranslated region (UTR). Excision of tagBFP2 leads to mCherry expression, providing a visible switch from blue-to-red fluorescence in cells where CRE is expressed and all daughter cells. (E) Representative image of mesoblast lineage descendants marked by the lineage tracing construct in an L4 larva (lateral view, ventral down; arrowheads point to BWM, brackets indicate egg-laying muscle precursors). (F) Representative images of the vulva region of RNAi-treated larvae. Anterior to the left, ventral down; scale bars, 10 m in all images. (G) Quantification of mesoblast lineage descendants per animal at the L4 stage following RNAi by feeding of synchronized L1 larvae for the indicated genes, in wild-type or fzr-1 mutant backgrounds. Twenty to 30 animals were scored for each condition.

Understanding in vivo function is particularly important because mammalian SWI/SNF complexes act as tumor suppressors and are altered in a wide variety of cancers. Mutations in the collective set of SWI/SNF subunitencoding genes have been found in 20% of examined human cancers (7, 10, 11). The broad spectrum of the identified genetic alterations makes it difficult to understand their exact oncogenic effects. While the BAF-specific subunit ARID1A is most frequently mutated, alteration of specific SWI/SNF subunits is associated with specific cancer types (7, 10, 11). Moreover, cancer-associated SWI/SNF missense mutations or deletions are often heterozygous or affect subunits for which paralogs exist [(6, 12), http://www.cbioportal.org]. Heterozygous mutations in genes encoding SWI/SNF subunits are also associated with intellectual disability disorders such as the Coffin-Siris syndrome (12). While haploinsuffiency likely explains the prevalence of genetically dominant loss-of-function SWI/SNF mutations in neurologic diseases, the unusual mutation spectrum of SWI/SNF genes in human cancer remains puzzling.

In this study, we characterize how partial versus complete loss of function of various SWI/SNF subunits affects the in vivo proliferation and differentiation of muscle precursor cells. We take advantage of the invariant cell lineage and advanced possibilities for controlled manipulation of the nematode Caenorhabditis elegans (13). Using lineage-specific gene knockout and protein degradation technologies, we demonstrate that various subunits of the SWI/SNF BAF complex contribute strong dosage-dependent functions in cell proliferation. As such, partial loss of function of BAF subunits leads to hyperplasia, which is enhanced by loss of negative cell cycle regulators. This indicates a tumor-suppressive function of SWI/SNF BAF, which resides, in part, on PcG protein opposition. Notably, we found that in the same cells, low levels of the SWI/SNF complex are required for cell proliferation, independently of the presence of PcG proteins or negative cell cycle regulators. Our single-molecule fluorescence in situ hybridization (smFISH) and RNA-sequencing (RNA-seq) studies show that acute inactivation of SWI/SNF BAF in muscle precursor cells rapidly alters the transcript levels of several hundred genes, including cyd-1 cyclin D, demonstrating that the complex is continuously required for the regulation of gene expression. Thus, in the same cell type and developmental decisions, a high dosage of SWI/SNF BAF subunits is needed for temporal arrest of cell division and PcG opposition, while a low level is required to sustain proliferation. We propose that similar dosage-dependent effects contribute to the selection of SWI/SNF partial loss-of-function mutations during carcinogenesis.

To investigate how the SWI/SNF complex regulates cell proliferation, we exploited the fact that cell divisions in the nematode C. elegans follow a well-characterized invariant pattern throughout development. Abnormalities resulting from aberrant regulation of proliferation-differentiation processes can therefore be readily recognized, monitored, and quantified on the basis of in vivo observations. Previously, we observed that a lineage-specific temperature-sensitive mutation in the SWI/SNF core subunit gene swsn-1 (SMARCC1/2) gives rise to hyperplasia during C. elegans postembryonic mesoderm development. When combined with loss of negative cell cycle regulators, this mutation induces a unique tumorous overproliferation phenotype (2).

To examine the role of specific SWI/SNF subunits in the regulation of proliferation, we performed RNA interference (RNAi) experiments for C. elegans genes predicted to encode components of the BAF and PBAF subcomplexes. These complexes share core subunits and several additional proteins, while differing in a few specific factors (Fig. 1, A and B). We focused on the mesoblast (M) lineage, which includes two sequential periods of cell cycle quiescence, proliferation, and muscle differentiation (Fig. 1C) (13). An integrated tagBFP2-to-mCherry lineage-tracing reporter and hlh-8 Twist promoter-CRE recombinase transgene (Phlh-8::CRE) facilitated the quantification of mCherry-positive mesoblast daughter cells (Fig. 1, D and E). Using this background, we observed that knockdown of the core ATPase subunit swsn-4 BRM/BRG1, the core subunit snfc-5 SNF5, and the BAF-specific subunit swsn-8 ARID1 increased the number of M descendants. Knockdown of either one of three PBAF-specific SWI/SNF subunits had limited effects (Fig. 1, F and G, and fig. S1, C and D). Simultaneous inhibition of negative regulators of the cell cycle further emphasized the different contributions of BAF versus PBAF subunits. Single knockout of the APC/C activator fzr-1 Cdh1, an inhibitor of cell cycle entry, did not alter the M lineage division pattern. However, fzr-1 loss enhanced the hyperplasia of M descendants when combined with knockdown of SWI/SNF core subunits and swsn-8 ARID1, but not when combined with PBAF-specific subunits (Fig. 1, F and G, and fig. S1, C and D). These data indicate that the SWI/SNF BAF complex contributes critically to the cell division arrest of muscle precursor cells.

RNAi of one of the core subunits, swsn-1 (SMARCC1/2), led to an unexpectedly variable number of mesoblast descendants, with animals showing a range from fewer to more than the normal number of cells (Fig. 1, F and G, and fig. S1, C and D). To test whether this reflects variability in RNAi-induced loss of function, we created conditional knockout alleles, as SWI/SNF null mutations are lethal. Using CRISPR-Cas9mediated genome editing, we introduced Lox sites in endogenous genes encoding the SWSN-1 and SWSN-4 core components, the BAF-specific SWSN-8 subunit, and the accessory subunit SWSN-2.1 BAF60 (Fig. 2A). We combined these loxed SWI/SNF alleles with the Phlh-8::CRE and tagBFP2-to-mCherry integrated transgenes to induce M lineagespecific gene deletion and reporter expression.

(A) Schematic of Lox sites (yellow diamonds) integrated into the endogenous SWI/SNF genes indicated. The swsn-4 ATPase-dead lysine-to-alanine mutation (K to A) is shown as a red block. Transcriptional start sites are indicated with arrows, introns are shown as black lines, and exons as colored blocks. (B) Representative images of mesoblast lineage descendants in wild-type and indicated SWI/SNF gene knockout animals. Arrowheads point at body-wall muscle (BWM), and brackets indicate egg-laying muscle precursors. Scale bar, 10 m. (C) Quantifications of mesoblast lineage descendants for the indicated genotypes, in the tail area (early dividing body wall muscles), and around the vulva (late-dividing egg-laying muscles). Note that, in contrast to RNAi, SWI/SNF gene knockouts lead to overproliferation of the early dividing BWM precursors and cell division arrest of the late-dividing egg-laying muscle precursor cells. Twenty-six to 35 animals were scored per condition.

The swsn-1, swsn-4, and swsn-8 knockout phenotypes differed greatly from those resulting from RNAi knockdown of the same genes and from the temperature-sensitive swsn-1 phenotype (Fig. 2, B and C, and fig. S2) (2). Specifically, instead of the RNAi-induced extra M descendants in the vulva region, the gene knockouts resulted in fewer late muscle precursors. Moreover, early-formed M cell descendants, which showed normal cell cycle arrest after RNAi treatment, overproliferated in the knockout strains (Fig. 2, B and C). Simultaneous inactivation of the fzr-1 cell cycle inhibitor synergistically increased the number of extra M lineage divisions in early development but did not suppress the reduced number of late M lineage divisions (fig. S2). On the basis of these knockout data, the SWI/SNF BAF complex appears to exert a critical function in cell number expansion, in addition to promoting cell cycle arrest and differentiation.

In contrast to the other conditional SWI/SNF mutants, swsn-2.1 knockout larvae remained normal. Two paralogous C. elegans genes, swsn-2.1 and swsn-2.2, encode BAF60-related SWI/SNF subunits, compared to three paralogs in mammals (14). When combined with swsn-2.2 RNAi, the swsn-2.1 knockout closely resembled the other conditional SWI/SNF gene knockouts (Fig. 2C). This indicates that swsn-2.1 and swsn-2.2 BAF60 act redundantly, and likely in combination with core subunits as well as SWSN-8 ARID1, in M-lineage control (Fig. 2C).

To assess whether the knockout phenotypes result from loss of the ATPase-dependent functions of the complex, we created an ATPase-dead swsn-4 allele by introducing a lysine-to-alanine (KA) mutation of a conserved residue that is essential for ATP hydrolysis (15) (Fig. 2A and fig. S2A). Because this mutant dies soon after hatching, we maintained the swsn4KA mutation in a trans-heterozygous combination with a wild-type or swsn-4Lox allele. Following M lineagespecific CRE expression, the swsn-4KA/swsn-4Lox mutant showed similar or somewhat stronger cell division abnormalities, compared with homozygous swsn-4Lox knockout animals (Fig. 2C and fig. S2). These data support that ATPase activity of the SWI/SNF BAF complex is required to promote both the cell cycle arrest of early body wall muscle (BWM) precursors and the expansion of egg-laying muscle precursor cells in late development.

We used promoter-fusion reporters and single-molecule FISH (smFISH) experiments to examine the proliferation-differentiation status of the SWI/SNF knockout cells. This showed residual hlh-8 Twist expression, which is normally restricted to undifferentiated muscle precursors (fig. S3, A and B) (16). Moreover, expression of the differentiation-specific myo-3 myosin heavy chain reporter was reduced at the time of normal BWM differentiation (17) (fig. S3, C and D). Further, expression of the S-phase cyclin cye-1 cyclin E was increased, and expression of the CDK inhibitor cki-1 Kip1 decreased compared with wild type, based on quantification of the number of mRNA copies per cell in smFISH experiments (fig. S3E). These data support that the extra cells in the conditional SWI/SNF knockout strains result from a prolonged proliferation-competent, not fully differentiated state compared with wild-type mesoblast descendants.

We considered whether different levels of SWI/SNF BAF may explain the opposite overproliferation and proliferation-arrest phenotypes. Dosage sensitivity of SWI/SNF complex functions has been implied by the spectrum of mutations detected in human cancer and intellectual disability disorders (11, 12, 18). When examined as the only alteration, a heterozygous swsn-4KA/wt BRG1/BRM mutation did not alter the mesoblast proliferation-differentiation pattern in our C. elegans model, with both the early-formed BWM and late-formed egg-laying muscle cells being normal in number and appearance (Fig. 3A and fig. S2D). By contrast, loss of the G1 inhibitors lin-23 -TrCP or cki-1 Kip1 leads to hyperplasia (2), which was enhanced by inactivation of a single swsn-4 allele. Specifically, we combined lin-23 RNAi and lineage-specific cki-1Lox knockout with a single inactive swsn-4 allele (swsn-4KA/wt) and observed significant increases in the number of M cell descendants (Fig. 3A). This haploinsufficiency indicates that the cell cycle arrest function of SWI/SNF BAF is highly sensitive to the expression level of the complex.

(A) Quantification of total number of mesoblast descendants for the indicated genotypes. *P 0.05, ****P 0.0001. (B) Quantification of mesoblast descendants for the indicated genotypes in the tail (early divisions) and around the vulva (late divisions). (C) Expression of SWSN-1::GFP in the M cell at 4 and 7 hours of larval development following gene knockout or gene knockout combined with protein degradation (+Prot. Deg.). Scale bars, 10 m. Arrows indicate mesoblast cells, outlined in zoom images (scale bars, 1 m). (D) Quantification of SWSN-1::GFP by fluorescence intensity in M for indicated times and genotypes (normalized to wild-type levels). (E) Quantifications of total numbers of mesoblast descendants for the indicated genotypes. (F) Representative images of strong overproliferation following SWSN-1 protein degradation and lin-23 RNAi (top), and of the one-cell arrest (arrow) after swsn-1 gene knockout together with protein degradation in lin-23 RNAi (bottom). Scale bars, 10 m. (G) Quantifications of mesoblast descendants for indicated genotypes, in the tail (early) and around the vulva (late). (H) Quantification of SWSN-1::GFP by fluorescence intensity in M descendants for indicated times and genotypes (normalized to wild-type levels). (I) Quantifications of total numbers of mesoblast descendants for the indicated genotypes and times. n numbers of worms scored for all panels in fig. S4D. A.U., arbitrary units.

More effectively than missing one allele of swsn-4, extra cell divisions result from RNAi of SWI/SNF BAF subunits, the swsn-1ts mutation (2), and, initially, SWI/SNF gene knockout. We hypothesized that in each of these situations, hyperplasia is associated with incomplete loss of SWI/SNF function. Following CRE-Loxmediated gene excision, residual mRNA and protein are initially present and will be depleted over time and with additional cell divisions. This means that a true null phenotype will follow gene excision after a certain delay and could be manifested as cell division arrest. To test this hypothesis, we sought to advance and increase SWI/SNF inactivation. First, we combined the swsn-1(os22ts) mutation with lineage-specific swsn-1 RNAi. Here, we expressed a swsn-1 double-stranded RNA (dsRNA) hairpin in the embryonic mesoblast, controlled by the hlh-8 Twist promoter. Compared with swsn-1(os22ts) and RNAi by feeding L1 larvae, the hairpin RNAi animals, with or without the swsn-1ts mutation, showed a phenotype more similar to the swsn-1 gene knockout, both in overproliferation of the early BWM precursors and in cell division arrest of the late-dividing egg-laying muscle precursors (Fig. 3B). Further, we also combined the lineage-specific hairpin RNAi with swsn-1 knockout to deplete swsn-1 mRNA earlier in development. This led to decreased numbers of both the early-dividing and late-dividing cells compared with the knockout alone. This illustrates that loss of SWI/SNF function may lead to either increased or reduced cell numbers, with stronger interference apparently resulting in fewer cells.

To further examine and control the degree of SWI/SNF gene inactivation, we made use of the combined insertion of a green fluorescent protein (GFP) tag and Lox sites into the endogenous swsn-1 gene (Fig. 2A). Following lineage-specific gene knockout, SWSN-1::GFP expression was still detectable in the mesoblast before (4 hours) and at the time (7 hours) of the first postembryonic cell division, although at progressively lower levels than observed in the wild type (Fig. 3, C and D). These observations support that despite SWI/SNF gene knockout, residual protein remains present during the early mesoblast divisions.

To create an acute null phenotype, we combined the conditional gene knockout with lineage-specific protein degradation. This was achieved by expressing an anti-GFP nanobody fusion protein (nanobody::ZIF-1) that targets GFP to a CUL-2based E3 ubiquitin ligase (19) and thereby triggers efficient SWSN-1::GFP proteolysis. To create a system for lineage-specific protein degradation, we integrated a transgene with a STOP-Lox cassette in between the ubiquitous eft-3 promoter and nanobody::ZIF-1 coding sequences (fig. S4, A and B). This way, CRE expression in the mesoblast can be used to induce protein degradation in parallel to swsn-1::gfp gene excision. This double inactivation approach reduced SWSN-1::GFP expression to undetectable levels before the first larval division (Fig. 3C). Nanobody-mediated degradation alone, without gene knockout, also led to strong SWSN-1::GFP depletion before the time of the first mesoblast cell division (Fig. 3D).

Notably, the effects of SWSN-1::GFP degradation alone versus degradation plus gene knockout were completely opposite. The combined SWSN-1::GFP protein degradation and gene knockout resulted in a complete block of cell division of the mesoblast in most animals (Fig. 3E). Even when combined with lin-23 knockdown, the single embryonic mesoblast did not enter cell division during larval development (Fig. 3, E and F, bottom). This result demonstrates that a certain level of the SWI/SNF complex is required for mesoblast proliferation. By contrast, lineage-specific SWSN-1::GFP protein degradation by itselfwithout gene knockoutresulted in strong overproliferation of early and late muscle precursor cells (Fig. 3G). The overproliferation of both early and late precursors was further enhanced by simultaneously interfering with negative cell cycle regulation (lin-23 RNAi; Fig. 3, E and F, top).

To further characterize the relationship between SWI/SNF levels and cell proliferation, we quantified SWSN-1::GFP levels over time during the course of the mesoblast divisions in the L1/L2 larval stages. We performed these experiments for three genetic backgrounds: the control reporter strain (wild type), the strains with the swsn-1::gfpLox conditional knockout alone, or the SWSN-1::GFP protein degradation alone (Fig. 3H and fig. S4C; note: combined knockout with protein degradation was excluded because of the complete arrest of M division). In parallel, we counted the numbers of mesoblast descendants over the same time period (Fig. 3I). We found that SWSN-1::GFP was initially invisible in the protein degradation alone strain (7 to 10 hours; Fig. 3, D and H), which corresponded to a temporary delay in cell division (Fig. 3I). At 14 hours of larval development, SWSN-1::GFP was reexpressed at low levels, and cell proliferation had resumed. Low levels of SWSN-1::GFP were maintained over the subsequent time points. Thus, SWSN-1 was present at a low level when protein degradation interfered with division arrest and induced overproliferation of M descendants (Fig. 3, H and I).

Upon swsn-1 knockout alone, SWSN-1::GFP levels declined only gradually and remained detectable throughout the initial rounds of cell division, which occurred at times similar to wild-type cell divisions (Fig. 3, H and I). At the time that wild-type cells normally exit the cell cycle, swsn-1 knockout cells briefly continued proliferation to reach cell quantities that resemble those scored in later stages (L4), and proliferation arrested during the time window in which SWSN-1::GFP reached undetectable levels (Fig. 3, B, H, and I). Together, these data demonstrate that the SWI/SNF complex exerts dosage-sensitive functions: A low amount is essential to allow proliferation, while a higher level is needed for temporal cell division arrest (fig. S4E).

To expand our analysis to a different cell type, we tested how different levels of SWI/SNF function affect the proliferation of epithelial cells. We chose to examine vulva formation, which is formed by descendants of the ventral cord precursor cells (Fig. 4A). The first postembryonic division of these cells generates a neuroblast and epithelial precursor. The central epithelial precursor cells acquire the potential to contribute cells to the vulva [vulval precursor cells (VPCs)]. Dependent on multiple integrated signal transduction pathways, these VPCs invariably generate 22 vulval cells during late larval development, which form a functional connection between the uterus and the outside by the adult stage (Fig. 4A) (20).

(A) The lineage of vulval development. The y axis indicates the time (hours) of larval development after hatching; vertical lines represent vulval precursor cells (VPCs), horizontal lines are cell divisions, and hyp7 denotes hypodermal fusion fate. (B) Maximum projection of the vulva after 40 hours of development, at the time when quantifications are carried out. Vulval nuclei express mCherry from the lineage-tracing reporter after Plin-31::CRE activity. Individual nuclei are easily identifiable. Scale bar, 10 m. See movie S1 for Z-stack. (C) Quantification of the number of vulval nuclei for the indicated genotypes. The lin-35(n745) mutation did not affect the VPC division pattern but was included to increase the efficiency of RNAi, as the neuroblast derived precursor (P) cells are relatively resistant to RNAi. Eleven to 90 animals were scored per condition. **P 0.01, ****P 0.0001. ns, not significant.

We combined our lineage-tracing reporter (Fig. 1D) with CRE expression from the lin-31 FOXB1 promoter, which is active in the VPCs. As expected, this resulted in mCherry-positive VPCs from the L2 stage onward (Fig. 4B). The most anterior of the six VPCs fuses with the surrounding epidermis (hypodermis) in 50% of the animals. We observed an equal distribution of animals with 5 or 6 VPCs, which always expanded to 22 cells by the end of the vulval cell divisions (Fig. 4, B and C, wild type). These cells expressed SWSN-1::GFP, as did all other cells throughout development (fig. S5A, top). Notably, weak inactivation of swsn-1, using the os22ts allele at a semipermissive temperature (20 or 21C) or RNAi, occasionally resulted in extra vulva cells, which was never observed in the wild type (Fig. 4C). In contrast, following swsn-1 RNAi or lineage-specific knockout, VPC daughter cell numbers were variably reduced. Complete inactivation through combined SWSN-1::GFP gene knockout and protein degradation resulted in a complete cell proliferation arrest of the VPCs (Fig. 4C; note: only five or six cells, corresponding to the undivided VPC number). We conclude that the SWI/SNF complex probably contributes to proliferation inhibition during vulva cell differentiation and that the essential SWI/SNF function in sustaining proliferation is conserved across multiple tissues in C. elegans.

SWI/SNF complexes oppose gene silencing by Polycomb repressor complexes PRC1 and PRC2 (11, 21, 22). Therefore, unrestrained PcG-mediated gene silencing might underlie the overproliferation and cell division arrest phenotypes of SWI/SNF knockout cells. To address this, we examined the contribution of MES-2, a H3K27 methyltransferase similar to EZH2, which is the critical catalytic component of the PRC2 complex (11, 21, 22). We generated GFP-tagged and mCherry-tagged endogenous alleles to visualize in vivo expression of MES-2 EZH2 and SWI/SNF BAF subunits. This revealed coexpression of PcG and SWI/SNF components throughout C. elegans development, and in all cell types, including the M lineage (fig. S5, A and B). Thus, removal of the antagonistic SWI/SNF complexes could, in principle, lead to prolonged or abnormal PcG-mediated gene silencing.

To be able to test whether unopposed PcG activity contributes to the SWI/SNF knockout phenotypes, we created conditional alleles of mes-2, again using CRE-Loxbased recombination of the endogenous gene, with or without a GFP tag (Fig. 5A). Nanobody::ZIF-induced protein degradation alone reduced MES-2::GFP below the detectable level (fig. S6A). As expected for PcG-mediated epigenetic repression, gene knockout of mes-2Lox, or even mes-2::gfpLox knockout combined with nanobody::ZIF-1 expression, did not immediately alter the M lineage. However, after four to seven rounds of cell division, mes-2 PRC2 inactivation resulted in a variable and partially penetrant premature arrest of cell divisionand possibly premature initiation of differentiation (fig. S6B).

(A) Schematic of Lox site integrations into the endogenous EZH2-related Polycomb gene mes-2, with Lox sites indicated by yellow diamonds. The transcriptional start site is indicated with an arrow, introns are shown as black lines, and exons as colored blocks. (B) Quantifications of mesoblast lineage descendants in the indicated genotypes, in the tail area (early-dividing BWM), and around the vulva (late-dividing egg-laying muscles). Thirteen to 27 animals were scored per condition. (C) Quantifications of total numbers of mesoblast lineage descendants in the indicated genotypes. Sixteen to 35 animals were scored per condition. *P 0.05, **P 0.01, ****P 0.0001.

When combined with knockout of mes-2, the overproliferation of early muscle precursor cells in SWI/SNF gene knockout animals was substantially reduced. The double knockout animals often showed close to wild-type BWM numbers (Fig. 5B). In agreement with previous RNAi experiments (2), these data support that SWI/SNF BAF promotes cell cycle arrest and differentiation of early muscle precursors, in part, by antagonizing Polycomb-mediated transcriptional repression.

Contrary to this early effect, the mes-2Lox knockout did not suppress the arrest of late mesoblast descendants in SWI/SNF mutants (Fig. 5B). The removal of mes-2 exacerbated the cell division arrest of SWI/SNF mutant late egg-laying muscle precursor cells (Fig. 5B). Because mes-2 and swsn-1 knockout both lead to reduced proliferation of late muscle precursors, we also examined the one-cell mesoblast arrest in L1. Acute double knockout of mes-2::gfp and swsn-1::gfp in the mesoblast gave rise to the single-cell arrest phenotype (Fig. 5C). Thus, PcG PRC2 loss, supported by complete absence of MES-2::GFP, did not alleviate the SWI/SNF complex requirement in cell proliferation. These data imply that the essential SWI/SNF complex function is separate from its antagonism of PcG-mediated gene repression.

The immediate arrest of swsn-1 null mesoblasts indicates that a SWI/SNF complex activity is continuously required. The arrested cells did not undergo cell death and remained present even in old adults. These observations appear consistent with SWI/SNF BAF requirement in inducing or sustaining cell proliferation. A previous study reported that SWI/SNF BAF promotes chromosome decatenation by promoting chromatin binding of topoisomerase IIA (23). While this function would be critical in mitosis, our quantitative measurements of DNA content showed that the arrested SWI/SNF null mesoblasts stopped the cell cycle before, or very early in, the S phase (Fig. 6A). We considered the possibility of a DNA damage or intraS phase checkpointinduced arrest, as SWI/SNF complexes have also been implicated in DNA damage repair and replication (6, 24). To test whether such checkpoints are responsible for the one-cell arrest, we added high concentrations of exogenous deoxynucleotide triphosphates (dNTPs), which has been reported to bypass DNA damagemediated arrests (25). Further, we also performed RNAi of chk-1 Chk1 and double RNAi of lin-35 Rb and cep-1 p53, conditions that also should prevent DNA damagemediated checkpoint arrest (26). As none of these conditions affected the single-cell arrest phenotype, evidence for checkpoint arrest was not obtained (Fig. 6B).

(A) Quantification of M cell DNA content in synchronized L1 larvae after 7 hours of development for the indicated genotypes. Wild-type M cells have undergone the S phase but not yet divided, leading to a 4C DNA content, whereas M cells in swsn-1::gfpLox + Prot. Deg. animals show an approximately 2C DNA content, indicative of cells arresting in the G1/early S phase. DNA was stained with propidium iodide, and DNA content normalized to that of differentiated embryonic BWM cells (2C). (B) Quantifications of mesoblast descendants for the indicated genotypes and treatments in L1 larvae. Fourteen to 28 animals were quantified per condition. (C) Principal components analysis (PCA) indicating clustering of replicate RNA-seq libraries, prepared from fluorescence-activated cell sorting (FACS)sorted 2000-cell samples from wild-type and swsn-1::gfpLox + Prot. Deg. L1 larvae at 5.5 hours of development. Samples A and B are true biological replicates, with RNA-seq libraries prepared from different starting populations of synchronized worms. Within A and B, duplicate/triplicate RNA-seq libraries were prepared from different 2000-cell populations, isolated from the same starting worm population, and can thus be considered semibiological replicates. (D) Volcano plot indicating differentially expressed genes between swsn-1::gfpLox + Prot. Deg. and wild-type isolated mesoblast cells at 5.5 hours of development. (E) Quantifications of the number of mRNA molecules per cell in smFISH experiments for the indicated genes, in synchronized L1 larvae at 6.5 hours of larval development (just before the usual first M division), and in wild-type compared with swsn-1::gfpLox + Prot. Deg. Twenty to 27 animals were scored per condition. **P 0.05.

We performed whole transcriptome RNA-seq to further characterize the arrested cells. We used pools of 2000 wild-type or acute swsn-1 knockout mesoblasts, isolated from synchronous cultures of L1 larvae at 5.5 hours of development (1 to 1.5 hours before the normal time of the first mitosis). Principal components analysis (PCA) showed a clear separation of the wild-type and mutant sequence data sets (Fig. 6C). Nevertheless, only a limited number of genes showed significantly different expression, of which the large majority were reduced in the SWSN-1depleted mesoblasts (213 genes; table S2). Among those, cell cycle genes were well represented, in particular presumed E2F targets (e.g., cdc-25.2, cdk-1, cyb-1 cyclin B1, and cyb-3 cyclin B3) (Fig. 6D, red boxes). These genes encode regulators of the G2/M transition and are expected to be expressed in wild-type cells, which at this stage are preparing for mitosis, but not in G1-arrested acute swsn-1 knockout cells. Therefore, the reduced transcript levels of these cell cycle genes may result indirectly from the early cell cycle arrest of swsn-1 mutant mesoblasts.

Regulators of the G1/S transition, such as cdk-4 CDK4/6, cye-1 cyclin E, cki-1 p21, and lin-35 Rb, showed similar expression in wild-type and arrested mesoblasts (Fig. 6D, gray boxes). As a possible exception, cyd-1 cyclin D transcripts were significantly reduced in one of the two biological replicates of swsn-1 mutant mesoblasts. As cyclin D transcription is an important regulator of cell cycle entry, we followed up on this finding by examining transcript numbers with single-cell resolution. Using smFISH, we observed that the number of cyd-1 mRNA molecules was much lower in swsn-1 mutant mesoblasts, compared with normal mesoblasts before the first cell division (Fig. 6E). These observations point to cyd-1 as a candidate for being a direct SWI/SNF target. RNAi of critical cyd-1 downstream targets, lin-35 Rb, and fzr-1 FZR1/Cdh1 (27), did not suppress the one-cell arrest, which indicates that cyd-1 is not the only critical gene to depend on the SWI/SNF complex. Together, our data demonstrate a continuous requirement for SWI/SNF BAF complexes in normal transcription and proliferation control.

In this study, we examined SWI/SNF and PcG complex functions in an in vivo system that provides a well-defined cellular context and reproducible developmental decisions. Our gene knockdown and knockout experiments demonstrate that in the same cell type and developmental stage, reducing the level of SWI/SNF core subunits or C. elegans ARID1 interferes with cell cycle exit, while complete inactivation of the identical subunits is incompatible with cell proliferation. Our quantifications of residual SWSN-1 protein amounts and cell numbers over time, following different treatments, indicate that hyperplasia is consistently associated with a reduced but detectable level of SWSN-1. The timing of overproliferation and gene expression studies support that the reduced SWI/SNF levels result in suspended cell cycle withdrawal associated with precursor cell differentiation. By contrast, a complete SWI/SNF inactivation appeared capable of arresting cell division at any point in the mesoblast and VPC lineages. Therefore, we conclude that a low level of SWI/SNF activity is continuously needed, independently of cellular context, to support cellular proliferation (fig. S4E). Together with EZH2 knockout studies, our data imply that the SWI/SNF BAF ATPase exerts a tumor suppressor function in the mesoblast lineage that requires a relatively high functional level and involves PcG opposition, while a low level is essential and sufficient to sustain cell proliferation. Our data are consistent with the model that partial loss-of-function SWI/SNF gene mutations are selected during carcinogenesis because they reduce a differentiation-promoting tumor suppressor activity without inactivating the critical requirement for the SWI/SNF complex.

That the function of SWI/SNF complexes is dosage sensitive is also indicated by the heterozygous and sometimes subtle mutations in SWI/SNF subunits identified in human cancer and neurologic disease (6, 12). Several mechanisms have been proposed to explain the remarkable mutation spectrum. Mutation or deletion of specific SWI/SNF subunits could lead to the formation of complexes with alternative or aberrant composition and activities (28, 29). In certain cases, mutations appear to lead to neomorphic gain of function or dominant-negative inhibition and thereby promote cancer formation or neurologic disease (12, 30). Moreover, mutations could affect the fidelity of DNA repair or chromosome segregation and indirectly contribute to tumorigenesis. Alternatively and more in line with our observations, various subunits of the SWI/SNF complex may be haploinsufficient if a single wild-type allele is not sufficient to maintain normal tumor suppression or development (68).

In our system, incomplete inactivation of multiple different BAF components, including the single ATPase and BAF-specific ARID1 subunit, results in very similar hyperplasia phenotypes. This indicates that the reduced SWI/SNF function, rather than the activity of complexes with an abnormal subunit composition, leads to overproliferation. Hyperplasia was observed early and reproducibly after SWI/SNF BAF gene knockout or protein degradation. This implies that the hyperplastic response in our system does not depend on a dominant-negative mechanism or on the generation of secondary mutations. In addition to dominant loss-of-function mutations, cancer typespecific gain of function and dominant-negative mutations affect specific SWI/SNF subunits. As such, common heterozygous mutations in the BRG1 ATPase selected in human cancer are likely to act in a dominant-negative way (30). Nevertheless, such mutations do not fully inactivate the wild-type allele, and residual BRG1 function is thus retained in the heterozygotes. The importance of residual SWI/SNF function seen in our system was previously revealed in synthetic lethal screens. Such screens and follow-up experiments demonstrated that ARID1B is essential in ARID1A mutant cancers, while tumors with mutations in the BRG1 (SMARCA4) ATPase depend on BRM (SMARCA2) (28, 31, 32).

Some cancer cells, however, appear to survive without SWI/SNF function. Malignant rhabdoid tumors are well known for their homozygous loss of SNF5 (SMARCB1), one of the core subunits of SWI/SNF complexes. Although initially expected to fully disable SWI/SNF complexes, SNF5-deficient cancer formation was found to depend on the presence of BRG1 (29). Recent studies revealed the existence of ncBAF complexes that do not contain SNF5, while removal of non-canonical BAF (ncBAF)specific subunits induces synthetic lethality in cancer cells lacking SNF5 (9, 33). Thus, in the best-described examples of homozygous SWI/SNF core subunit loss, cell proliferation still depends on the presence of residual SWI/SNF complex activity, in this case provided by the atypical SWI/SNF ATPase ncBAF (9, 33). In a specific small cell carcinoma of the ovary and a subset of cancer-derived cell lines, biallelic mutation of BRG1 coincides with transcriptional silencing of the BRM locus (6, 10, 34). Although it is difficult to exclude that a trace amount of residual BRM permits the proliferation of these cells, activation of compensatory mechanisms may allow complete loss of SWI/SNF ATPase activity in some cell types.

In our study, interfering with any one of the BAF complex subunits induced hyperplasia or cell proliferation arrest, depending on partial or complete removal. We characterized this thoroughly for SWNF-1, the sole homolog of the scaffold subunits BAF155/170. This subunit is shared between all SWI/SNF complexes, and without it, no version of the complex can assemble (9). Therefore, rather than changing the SWI/SNF subunit composition and allowing the formation of aberrant residual complexes, we affected the global levels of SWI/SNF activity. As such, our data support that the complete loss of all SWI/SNF ATPase activity is incompatible with cell proliferation and that there are perhaps overlapping core functions for all of the different SWI/SNF variants in promoting a proliferation-competent state.

Several mechanisms could underlie the dosage sensitivity of SWI/SNF functions. In our system, a high dosage is needed when cells transition to a differentiated state, at which time many loci are transcriptionally activated or silenced. Compared with altering the chromatin state during gene activation or silencing, the maintenance of gene expression may require lower levels of the SWI/SNF complex. If true, then partial SWI/SNF inactivation will interfere with differentiation but not continued proliferation, which would provide a mechanism promoting tumorigenesis. Possibly in support of such a mechanism, SMARCB1 or SMARCA4 gene knockout in mouse embryonic fibroblasts (MEFs) most significantly reduced the transcript numbers from genes with gene ontology (GO) terms associated with development and differentiation (35).

In our experiments, the essential SWI/SNF function appeared independent from PRC2-mediated gene silencing. Other activities of the complex, such as chromatin remodeling, could be critical for mesoblast and VPC proliferation. Both knockout MEF cells and embryonic stem cells with heterozygous dominant-negative alleles of BRG1 showed a broad reduction in chromatin accessibility at active enhancers, which was remarkably associated with loss of H3K27Ac rather than increased PcG protein binding (30, 35). These studies did not reveal whether widespread transcriptional deregulation, reduced expression of some critical genes, or other defects are incompatible with cellular proliferation when the SWI/SNF activity falls below a critical level. Our RNA-seq analysis showed that the acute arrest of mesoblast proliferation occurred when the expression of a limited number of genes was significantly altered. We identified C. elegans cyclin D as one of the genes whose transcription is acutely sensitive to SWI/SNF inactivation. In contrast to cyd-1 mutants, the proliferation arrest associated with strong SWI/SNF loss was insensitive to knockdown of cell cycle inhibitors (27, 36). Therefore, we expect that the down-regulation of cyd-1 and other critical genes is responsible for the tight cell cycle arrest. Two recent human cancer studies also concluded that SWI/SNF ATPases promote cyclin D1 expression (37, 38).

That loss of function of SWI/SNF subunits can lead to opposite phenotypes (hyperplasia versus division arrest), depending on residual complex levels, provides support for the clinical exploration of cancer cell vulnerabilities that result from SWI/SNF gene mutations (39). At the same time, the delicate balance between dosage-dependent SWI/SNF and PcG regulators observed in our system illustrates that the outcome of targeted therapies will be difficult to predict and highly context dependent. The many parallels between observations in our system and human cancer cells support that efficient genetic screens in C. elegans may help identify synthetic lethal interactions that are broadly associated with SWI/SNF loss and cause little toxicity in normal cells.

Genotypes of all strains used in this study are listed in table S1. C. elegans was cultured on nematode growth media (NGM) plates seeded with OP50 bacteria and generally maintained at 20C. Strains containing the pha-1(e2123) mutation were maintained at 15C and shifted to 25C for mutant phenotype analysis.

Bacterial cultures of Escherichia coli HT115 containing L4440 empty vector or vector with genomic or open reading frame (ORF) gene inserts were grown overnight, induced with 1 mM isopropyl--d-thiogalactopyranoside (IPTG) for 1 hour, concentrated 2.5 times, and seeded onto NGM plates containing tetracycline (12.5 g/ml), ampicillin (100 g/ml), and 2 mM IPTG. Early L1 larvae were exposed to feeding RNAi for knockdown of SWI/SNF components, and the number of mesoblast descendants was analyzed in late L3/early L4 animals of the same generation. swsn-1, swsn-4, swsn-8, swsn-7, swsn-9, swsn-2.2, swsn-3, swsn-6, and phf-10 RNAi vectors were cloned by ligating a ~1000-bp complementary DNA (cDNA) fragment into the L4440 vector. When examining contributions of lin-23, chk-1, lin-35, or cep-1, L4 animals were placed on RNAi plates and the F1 was analyzed.

Single-copy integration of the recombination reporter (readoutlox; Peft-3::LoxP::egl-13NLS::tagBFP2::tbb-2UTR::LoxP::egl-13NLS::mCherry::tbb-2UTR) into chromosomes III and V standard MosSCI sites was performed as described in (2). The Phlh-8::swsn-1::unc-54 untranslated region (UTR) hairpin construct was generated by inserting a ~1100-bp swsn-1 cDNA fragment, followed by the antisense sequence of the same ~1100-bp swsn-1 cDNA fragment including a stop codon, after the Phlh-8 promoter. See fig. S5 for details on the anti-GFP nanobodyZIF-1 construct.

All Lox insertions, as well as the ATPase dead swsn-4 mutant, were generated by temperature-sensitive pha-1 coconversion (40) using single-stranded DNA oligonucleotides with 40-bp homology arms as repair templates. For pha-1 coconversion, seven times outcrossed pha-1(e2123) young adults, grown at the permissive temperature of 15C, were injected into the gonads with the following injection mix: U6::gRNA target construct (50 ng/l), pJW1285 (60 ng/l; U6::gRNA pha-1 and Cas9 construct), and single-stranded DNA repair templates (50 ng/l) for pha-1 as well as the appropriate target. Injected worms were immediately placed at 25C. F1 rescued pha-1 animals were analyzed by polymerase chain reaction (PCR) amplification, using primers flanking the Lox insertion site, for the presence of a reduced-mobility DNA band indicative of Lox site insertion. The swsn-4 K-to-A mutation was generated in a strain with a GFP-expression cassette, eft-3::GFP::2NLS::tbb-2 3UTR, integrated on chromosome IV close to the swsn-4 locus. By selecting GFP-positive animals, the homozygous lethal swsn-4 ATPase-dead mutation can be easily maintained. All mutations were sequence verified. The swsn-1::egfpLoxP strain was generated by inserting enhanced GFP (eGFP) using the self-excising cassette (SEC) method (41) into wild-type N2 worms, which leaves a LoxP scar. The injection mix contained the following: U6::gRNA target construct (100 ng/l), pDD268 eGFP SEC vector (20 ng/l) with 150-bp swsn-1 left homology arm and swsn-1 600-bp right homology arm, Peft-3::Cas9 (50 ng/l; Addgene 46168), and Pmyo-2::tdTomato (2.5 ng/l). The second LoxP site was introduced by crossing the strain with pha-1(e2123) and by temperature-sensitive pha-1 coconversion as described above. The mes-2::egfpLoxN strain was made by inserting eGFP with a LoxN site in one of the GFP introns into a strain that already contained a LoxN site in the first intron of mes-2.

For analysis and quantification, animals were mounted on 3% agarose slides, using tetramisole (10 mM) in M9 plus 0.05% Tween (36). Combining Phlh-8::CRE with the lineage-tracing reporter allowed rapid identification of cells in the mesoblast lineage (mCherry positive), whereas Plin-31::CRE was used to visualize VPC daughter cells. The numbers of M descendants and VPC descendants were quantified by counting the number of mCherry-positive cells at specific developmental times. Images of the proliferation phenotypes were obtained using a Zeiss LSM700 confocal microscope. SWSN-1::GFP fluorescence intensities were quantified by using the ImageJ measurement tool, selecting the region of interest (ROI; M cell nucleus), and subtracting the background signal (same ROI, not including GFP-positive cells in the same larva). At least 16 larvae per condition were measured.

To quantify vulval nuclei, animals were synchronized using hypochlorite treatment and grown for 40 (tracing-reporter controls, swsn-1ts, or knockout) or 50 hours [strains containing lin-35(n745) mutation and protein degradation strains) at 20C unless indicated otherwise. Still images and Z-stacks were taken using a 63/1.4 numerical aperture lens on a Zeiss Axioplan microscope or a Zeiss confocal microscope, with a slice interval of 0.32 m for Z-stacks. Vulval cell quantifications were performed on the basis of Z-stacks.

smFISH was performed essentially as described in (2). Cy5-coupled probes against mRNAs of interest were ordered from Stellaris (http://singlemoleculefish.com/), with 23 to 48 probes per gene of interest ranging from 18 to 22 bp in length. L1 or L4 animals were fixed for 30 min at room temperature (RT) in 400 l of Bouins fixative + 400 l of methanol and 10 l of -mercaptoethanol, three times freeze thawed and again tumbled for 30 min in fixative at RT. For permeabilization, the fixative was removed and exchanged for borateTriton-mercaptoethanol (BTB; 1 borate buffer, 0.5% Triton, and 2% -mercaptoethanol) solution. Animals were tumbled three times for 1 hour in BTB solution at RT. BTB solution was then replaced with wash buffer A (Stellaris) containing 20% formamide, and then with 100 l of hybridization solution containing smFISH probes to a final concentration of 0.25 to 0.5 M, and incubated overnight at 32C. Samples were washed in wash buffer A without formamide and incubated with 0.05 ng of 4,6-diamidino-2-phenylindole (DAPI) in wash buffer A for 30 min at 32C. After a final wash in wash buffer B (Stellaris), animals were mounted on slides with Vectashield mounting medium and imaged within 4 hours. Images were acquired using a Nikon Eclipse Ti Spinning Disk confocal microscope, using a 100 objective. The tetramethylrhodamine (TMR) (mCherry) spots were used to draw an ROI around (mCherry-positive) M lineage descendants in ImageJ, in which the number of Cy5 fluorescent mRNA spots was quantified using the ComDet plugin in ImageJ [https://imagej.net/Spots_colocalization_(ComDet)].

Sample sizes were not predetermined; instead, all available animals of the right stage and genotype were counted. smFISH data are included from at least 8 independent animals, and reporter expression and cell numbers from at least 10 independent animals. Graphs and data analysis were produced using GraphPad Prism 6.05. Plots indicate all data points and the mean (average) SEM. As the data essentially fit normal distributions, unpaired two-tailed Students t tests were used to examine statistical significance of the difference between means.

Propidium iodide staining was carried out after Carnoys fixation as previously described (42). For DNA quantification, Z-stacks were acquired using a Zeiss LSM700 confocal microscope. Maximum projections (SUM) were made in ImageJ from all the stacks in which the M cell DNA was visible, and pixels were quantified using ImageJ. Postmitotic, differentiated BWM cells (2C) were quantified in the same manner and used as a reference.

The C. elegans L1 larval cell isolation protocol was adapted from (36). To generate large amounts of synchronized L1 larvae, worms were grown in S medium in liquid culture for two generations (to enrich for gravid adults) and bleached. Eggs were hatched overnight (for 18 to 22 hours) in S medium without food, and starved L1 larvae were split into three aliquots and put back into S medium with OP50 for 5.5 hours. Cultures were put on ice for 15 min, spun down at 1300g, and washed two times in M9 and once in H20. L1 larvae were then transferred to 1.5-ml Eppendorf tubes (20 to 40 l of L1 pellet per Eppendorf) and spun down at 16,000g. Larvae were treated with SDSdithiothreitol (DTT) solution (20 mM Hepes, pH 8.0, 0.25% SDS, 200 mM DTT, and 3% sucrose) for 2 min, washed six times in egg buffer (25 mM Hepes, pH 7.3, 118 mM NaCl, 48 mM KCl, 2 mM CaCl2, and 2 mM MgCl2, adjusted to 340 5 mOsm with H2O), and then treated with pronase E (20 mg/ml) in L15/fetal bovine serum (FBS) buffer [10% FBS and 1% penicillin-streptomycin (Sigma, P4458) in L15 insect medium, adjusted to 340 5 mOsm with 60% sucrose] for 30 to 40 min. After 10- and 20-min incubation in pronase E, a pellet pestle motor with a pellet pestle adapted to 1.5-ml microtubes (Sigma, Z359971 and Z359947) was used for 1 min on each sample. Last, cell preparations were washed three times in L15/FBS, spun down at 9600g for 5 min between each wash, and resuspended in 1 ml of L15/FBS.

Cell preparations were allowed to settle on ice for 30 min, and the top 850 l of the supernatant was removed and transferred to a new Eppendorf tube for fluorescence-activated cell sorting (FACS). Cells were sorted according to mCherry-positive signal using a BD FACSAria III (BD Biosciences). For each sample, 2000 cells were sorted into L15/FBS buffer. In one session, three wild-type and three mutant samples were sorted. Immediately after sorting, cells were spun down at 12,000g for 5 min, resuspended in TRIzol, and frozen at 80C.

cDNA libraries were prepared according to a combination of the CEL-Seq and CEL-Seq2 protocols with some modifications (43, 44). RNA was precipitated using chloroform/isopropanol precipitation at 20C for 48 to 72 hours and washed once in 75% ethanol. CEL-Seq2 primers were used (one unique primer per sample), with each primer containing an anchored polyT, a 6-bp unique barcode, 6-bp Unique molecular identifier (UMI), a 5 Illumina adaptor, and a T7 promoter. The CEL-Seq1 protocol was followed for a first round of reverse transcription and cDNA cleanup followed by in vitro transcription, as well as for fragmentation of amplified RNA (aRNA), as described (43). aRNA was run on an Agilent bioanalyzer [RNA picochromatin immunoprecipitation (ChIP)] for quality control and quantification. The CEL-Seq2 protocol was followed for a second round of reverse transcription and PCR amplification, as described (44). cDNA was amplified for 11 to 15 cycles depending on aRNA amounts, run on an Agilent bioanalyzer (DNA pico-ChIP), quantified using a Qubit, and 1 to 2 ng was sequenced with 5% coverage on an Illumina NextSeq500.

Data analysis was carried out in R version 3.4.4. PCA was performed with the plotPCA function after carrying out variance-stabilized transformation on the data. Differential gene expression was analyzed using DESeq2 (default settings) using a padj cutoff of 0.1 (45).

Acknowledgments: We are grateful to members of the Korswagen and Van Oudenaarden groups at the Hubrecht Institute for help with RNA-seq experiments, and to P. Verrijzer and members of the Van den Heuvel and Boxem groups for input, discussion, and comments on the manuscript. Several strains were provided by the CGC, which is funded by the NIH National Center for Research Resources (NCRR). Funding: This work was supported by Worldwide Cancer Research (WCR) grant 14-1294, and M.G. was supported by the EMBO Long-Term Fellowship ALTF 991-2016. Author contributions: A.v.d.V. performed most of the SWI/SNF knockdown and knockout experiments, analyzed the results, and cowrote the paper. M.G. generated cki-1Lox and mes-2::gfpLox strains; performed the smFISH, DNA and protein quantifications, and RNA-seq experiments; analyzed the results; and cowrote the paper. V.P. generated the anti-GFP nanobody::ZIF-1 construct and strains, performed the VPC experiments, and contributed to the experimental design. S.v.d.H. conceived the study, acquired funding, provided guidance with experimental design, and cowrote the manuscript. Competing interests: The authors declare that they have no competing interests. Data and materials availability: All data needed to evaluate the conclusions in the paper are present in the paper and/or the Supplementary Materials. Additional data related to this paper may be requested from the authors.

See more here:
Dose-dependent functions of SWI/SNF BAF in permitting and inhibiting cell proliferation in vivo - Science Advances

Human Embryonic Stem Cells (HESC) Market to witness an impressive growth during – News by aeresearch

Latest Report on Human Embryonic Stem Cells (HESC) Market size | Industry Segment by Applications ((Research, Clinical Trials and Others), by Type (Totipotent Stem Cells, Pluripotent Stem Cells and Unipotent Stem Cells), Regional Outlook, Market Demand, Latest Trends, Human Embryonic Stem Cells (HESC) Industry Growth & Revenue by Manufacturers, Company Profiles, Shares, Forecasts 2026. Analyzes current market Analysis and upcoming Few years growth of this industry.

The Human Embryonic Stem Cells (HESC) Market report provides a detailed overview of the industry including both qualitative and quantitative information. Human Embryonic Stem Cells (HESC) market with detailed market segmentation by return type, end-user and geography. The global Human Embryonic Stem Cells (HESC) market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the leading Human Embryonic Stem Cells (HESC) market players and offers key trends and opportunities in the market. The global Human Embryonic Stem Cells (HESC) market is segmented on the basis of return type and end-user.

The report also includes the profiles of key companies along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, components and services offered, financial information, key development in past five years.

Request Sample Copy of this Report @ https://www.aeresearch.net/request-sample/190045

Global Human Embryonic Stem Cells (HESC) Market Segment by Manufacturers, this report covers:

Global Human Embryonic Stem Cells (HESC) Market Segment by Applications, can be divided into

Global Human Embryonic Stem Cells (HESC) Market Segment by Type, covers:

The Human Embryonic Stem Cells (HESC) market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.

Reason to Buy:

Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the global Human Embryonic Stem Cells (HESC) marketHighlights key business priorities in order to assist companies to realign their business strategies.The key findings and recommendations highlight crucial progressive industry trends in the Ribbon Fiber Optic Cable market, thereby allowing players to develop effective long-term strategies.Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.Scrutinize in-depth global market trends and outlook coupled with the factors driving the market, as well as those hindering it.Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to products, segmentation and industry verticals.The report analyzes factors affecting Human Embryonic Stem Cells (HESC) market from both demand and supply side and further evaluates market dynamics effecting the market during the forecast period i.e., drivers, restraints, opportunities, and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA and South & Central America after evaluating political, economic, social and technological factors effecting the Human Embryonic Stem Cells (HESC) market in these regions.

Table of Contents:

IntroductionKey TakeawaysResearch MethodologyHuman Embryonic Stem Cells (HESC) Market LandscapeHuman Embryonic Stem Cells (HESC) Market Key Market DynamicsHuman Embryonic Stem Cells (HESC) Market Global Market AnalysisHuman Embryonic Stem Cells (HESC) Market Revenue and Forecasts to 2026 Product TypeHuman Embryonic Stem Cells (HESC) Market Revenue and Forecasts to 2026 ApplicationHuman Embryonic Stem Cells (HESC) Market Revenue and Forecasts to 2026 Geographical AnalysisIndustry LandscapeHuman Embryonic Stem Cells (HESC) Market, Key Company Profiles

Request Customization on This Report @ https://www.aeresearch.net/request-for-customization/190045

More:
Human Embryonic Stem Cells (HESC) Market to witness an impressive growth during - News by aeresearch

Qatar- Georgetown student takes Islamic bioethics research at QF to Washington and wins – MENAFN.COM

(MENAFN - Gulf Times) An academic paper analysing the Muslim perspective on the controversial use of stem cell research has won Amna al-Essa, a Georgetown University in Qatar (GU-Q) student, second place in the Bioethics Research Showcase sponsored by the Kennedy Institute of Ethics in Washington, DC, one of the oldest academic ethics centres in the world.Amna's winning entry was judged by an interdisciplinary panel of judges and announced during a virtual awards ceremony.In the paper, she explores the background behind the Islamic rulings guiding the use and limitation of embryonic stem cells in the medical sciences, a field of research that holds great promise for the treatment of degenerative conditions and the understanding of human development.The medical technology uses cells from human embryos which has raised a host of ethical concerns and debates across cultures and countries.Muslim countries also face these debates, explained Amna, but often lack the needed guidance of a religious authority ruling.'There is a pressing need to address continuing ethical concerns and questions that arise from societal, cultural and religious perspectives on issues that transgress into matters of prohibitions and permissibility in Islam.She was encouraged to submit her paper for competition by the instructor of her Islam, Culture and Bioethics course, associate research professor Dr Ayman Shabana.He is also the director of the Islamic Bioethics Project at GU-Q, which has been supported by three consecutive grants from Qatar National Research Fund's National Priorities Research Programme.'Being at GU-Q has definitely deepened my interest in the connections between Islam and bioethics. We are offered this great opportunity to be exposed to multiple fields and wider disciplines, like theology, philosophy and politics. This opportunity has allowed us to cultivate our own selves and knowledge based on our personal interests across different fields.An International Politics major student at GU-Q, a Qatar Foundation (QF) partner institution, Amna said it was during her pursuit of the Theology minor that she became interested in bioethics.'I have always had a passion for science and medicine, which is why I decided to pursue them within the realm of liberal arts. Studying theology at Georgetown has widened my horizons to think about issues in the medical field and to consider how contemporary religious beliefs and practices deal with those issues.The Showcase is a jurieddigital exhibition of under-graduate research in a varietyof categories and disciplineson the ethics of health,the environment and thebioethics of emerging technologies.The virtual award ceremony as well as Amna's winning paper are available for viewing on the Kennedy Institute of Ethics website.

MENAFN1405202000670000ID1100166468

Go here to see the original:
Qatar- Georgetown student takes Islamic bioethics research at QF to Washington and wins - MENAFN.COM

Millions of Human Cells Have Been Grown Inside Mice Embryos – Newsweek

Scientists have created millions of human cells in mouse embryos, in a technique which they hope could one day be used in a variety of ways, from growing organs for life-saving transplants to finding treatments for diseases including COVID-19.

The study centred around what are known as stem cells, which can grow into many different types of cells. Researchers at the State University of New York at Buffalo and Roswell Park Cancer Institute injected 10 to 12 human stem cells into 3.5-day-old mouse embryos.

After 17 days, millions of human cells formed in 10 mouse embryos. They included eye, liver, and red blood cells, which each represent one of the three types of cells we are made up of. The human cells accounted for between 0.1 to 4 percent of the cells in 14 of the mouse embryos, creating a chimera.

Professor Jian Feng of the Jacobs School of Medicine and Biomedical Sciences at State University of New York at Buffalo who co-authored the study published in Science Advances, told Newsweek: "This will enable the generation of human cells, tissues or even organs in animals."

Feng said he was most surprised that his team were able to produce lots of human red blood cells for reasons that are unclear. This shows that the human stem cells developed faster in the mouse embryos, as such cells would not be found in a human embryo until after about seven to eight weeks, he explained.

The study also showed how the team were able to turn stem cells from a primed to nave state in order to grow the different cells. While nave cells aren't on track to become a specific type of cell, primed stem cells are on the path to developing into a specific type of cell.

They did this by inhibiting an enzyme in primed human stem cells for three hours. This enabled the newly nave human stem cells to grow with nave mouse cells in the embryos. The technique previously used to create nave human stem cells wasn't able to create human cells of different types in mouse embryos.

Feng said the technique could be used to produce mice which are better models of human diseases, "particularly infectious diseases that specifically or preferentially impact human, e.g., COVID-19.

"It is possible to make human immune cells or cells of the respiratory system in a mouse with this technology. Such chimeric mice would be very useful for studying COVID-19, which gravely impacts humans, not barely affects mice."

The method could also be used to generate organs in large farm animals, like pigs, for organ transplants in humans. But the approach would need to be significantly developed to translate what the team found in mice to large animals such as pigs, according to Feng.

"There are lots of hurdles to go through before it can be done. The human organs need to be free of pig cells. This would be very hard. One potential pathway is to understand how it works in a chimeric pig and try to develop an artificial system to grow human organs. If this can be realized, many patients who are waiting for organ transplant will be saved."

However, Feng acknowledged: "There are lots of things that we do not understand. More research is needed to understand how exactly human stem cells develop in a mouse embryo, whether it is possible to make even more human cells of a particular kind, for example, so the chimera can be used to study diseases or provide cells for transplantation. It is still at the early stage of this field."

Read more

Deborah Gumucio, Professor Emerita of the Department of Cell and Developmental Biology and Department of Internal Medicine at University of Michigan Medical School, who did not work on the project, told Newsweek: "This study's major advance is the establishment of culture conditions that permit the relatively (compared to previous studies) robust contribution of human embryonic stem cells to multiple organs/tissues in intact mouse embryos.

"This could eventually permit the study of human cells in the context of fully functioning organs, thereby offering real potential for new and exciting scientific exploration.

"A very surprising aspect to me was the amazing speed with which the human red cells and photoreceptors developed in the context of the mouse embryo. Of course, the functional properties of these human cells have yet to be examined.

"It makes one wonder, if we were to increase the amount of chimerism (maximally 4 percent in this study), would the developmental properties of the cells resemble those seen in mouse or human?" said Gumucio.

Although the work is an important proof of concept, Gumucio said: "In any groundbreaking study like this, tremendous potential sits side-by-side with limitations and questions that must be answered with further research.

"Here, the authors were able to achieve 0.14 to 4 percent chimerism. This might be enough to study the properties/behavior of the human cells in their new murine [mouse] homes, but, since we know that much of cell behavior is directed by cell to cell communication, will these cells behave like human cells or mouse cells?

"Certainly, the speed-up in development mentioned above suggests that the mouse environment does in fact affect human cellular development. Whether it also affects cell function will need to be further explored in each tissue/organ context."

Noa Novershtern of the Department of Molecular Genetics at the Weizmann Institute of Science, Israel, who didn't work on the study, told Newsweek: "As always, such exciting findings need to be repeated and confirmed by other labs. In addition, there is still a need to test carefully whether the human cells gained the function of the mouse tissue they reside in, as there is a possibility that they populate the embryo but do not function correctly."

Continue reading here:
Millions of Human Cells Have Been Grown Inside Mice Embryos - Newsweek

AgeX Therapeutics Reports First Quarter 2020 Financial Results and Provides Business Update – Business Wire

ALAMEDA, Calif.--(BUSINESS WIRE)--AgeX Therapeutics , Inc. (AgeX: NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, reported financial and operating results for the first quarter ended March 31, 2020.

The human tragedy of this pandemic has long tentacles that effect numerous businesses including AgeX, said Greg Bailey M.D., Chairman. Given the current global economic landscape, and the changes that businesses will need to make to accommodate to a post pandemic world, we feel that new business model aligns well to be able to function in this new environment. We see enormous opportunity to license and joint venture PureStem and HLA-G while implementing a definitive plan to begin preclinical trials on tissue regeneration under the leadership of Michael West and Michael May. We will update you in the future as these plans progress.

AgeX has completed a company restructuring to help set it up for success in the future. The combination of company priorities, cash position and the COVID-19 pandemic led to employee lay-offs designed to support the evolution of AgeX's current team to execute on strategic business goals going forward and to ensure cash is directed at near-term priorities to deliver maximum shareholder value. AgeX has a dual business strategy to diversify risk and maximize opportunities. It plans to continue to pursue its licensing and collaboration strategy for its two primary technology platforms, UniverCyte immunotolerance technology for the generation of universal cells, and PureStem cell derivation and manufacturing technology for the production of therapeutic cells with potential advantages, including industrial scalability and lower manufacturing costs. Since the launch of its licensing and collaboration strategy in January 2020, AgeX has delivered a research collaboration in Japan focused on developing universally transplantable cells for therapeutic use based on UniverCyte, entered into a neural stem cell therapy research collaboration for neurological disorders utilizing PureStem at a California University, and AgeX licensee ImStem Biotechnology received the first-ever clearance of a cell therapy derived from AgeXs embryonic stem cells by the FDA to enter human studies.

In addition, AgeX remains committed to pursuing in-house cell therapy product development and plans to raise money to build the optimal team to deliver on its products, AGEX-BAT1 for metabolic diseases such as type II diabetes and AGEX-VASC1 for tissue ischaemia. AgeXs budgetary and personnel adjustments will result in the deferral of in-house product development and may also lead to AgeX seeking arrangements with other companies in the cell therapy or biopharma industry for the development of its product candidates and technology, or outsourcing of some of that work to service providers until further funding can be obtained to rebuild in-house research and development staff for one or more of those programs. Development of AgeXs iTR technology may be done at AgeXs subsidiary Reverse Bioengineering, Inc. subject to successful financing of the subsidiary.

Upwards of 80% of healthcare expenditures in the United States relates to chronic degenerative disease and aging is a principle underlying cause of such conditions, said Michael D. West, Ph.D., AgeXs Chief Executive Officer. Therefore, the ability to manufacture to scale young clinical-grade cells capable of regenerating functionality in diverse tissues of the body has the potential to transform healthcare as we know it today. Perhaps even more noteworthy is the potential of reversing developmental aging in the body itself through AgeXs iTR technology. Our goal in the coming year is to advance the development of our intellectual property with the goal of bringing value to our shareholders.

Q1 Highlights

Liquidity and Capital Resources

AgeX is in need of additional capital to finance its operations. On March 30, 2020, AgeX entered into a Secured Convertible Facility Agreement (the New Loan Agreement) with Juvenescence Limited pursuant to which AgeX may borrow funds from time to time. On April 1, 2020 AgeX drew the initial $500,000, and may draw additional funds from time to time subject to Juvenescences discretion, prior to the contractual repayment date on March 30, 2023. AgeX may not draw down more than $1 million in any single draw. More information about the New Loan Agreement can be found in AgeXs Annual Report on Form 10-K and Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on March 30, 2020 and May 14, 2020, respectively.

On April 13, 2020, AgeX obtained a loan in the amount of $432,952 from Axos Bank under the Paycheck Protection Program (the PPP Loan). The PPP Loan will bear interest at a rate of 1% per annum. No payments will be due on the PPP Loan during a six month deferral period commencing on the date of the promissory note. Commencing one month after the expiration of the deferral period, and continuing on the same day of each month thereafter until the maturity date of the PPP Loan, monthly payments of principal and interest will be due, in an amount required to fully amortize the principal amount outstanding on the PPP Loan by the maturity date. The maturity date is April 13, 2022. The principal amount of the PPP Loan is subject to forgiveness under the PPP to the extent that PPP Loan proceeds are used to pay expense permitted by the PPP, including payroll, rent, and utilities (collectively, Qualifying Expenses), during the time frame permitted by the PPP. AgeX intends to use the PPP Loan amount for Qualifying Expenses. However, no assurance is provided that AgeX will obtain forgiveness of the PPP Loan in whole or in part.

Staff Reductions

During April 2020, AgeX initiated staff layoffs that affected 12 employees, primarily research and development personnel. AgeX has paid approximately $105,000 in accrued payroll and unused paid time off and other benefits and expects to recognize approximately $194,800 in restructuring charges in connection with the reduction in staffing, consisting of contractual severance and other employee termination benefits, substantially all of which are expected to be settled in cash. The staff reductions followed AgeXs strategic review of its operations, giving consideration to the status of its product development programs, human resources, capital needs and resources, and current conditions in the capital markets resulting from the COVID-19 pandemic.

Going Concern Considerations

As required under Accounting Standards Update 2014-15, Presentation of Financial Statements-Going Concern (ASC 205-40), AgeX evaluates whether conditions and/or events raise substantial doubt about its ability to meet its future financial obligations as they become due within one year after the date its financial statements are issued. Based on AgeXs most recent projected cash flows, and considering that loans from Juvenescence in excess of an initial $500,000 advance under the New Loan Agreement will be subject to Juvenescences discretion, AgeX believes that its cash and cash equivalents, the $500,000 loan under the New Loan Agreement, the PPP Loan and reduction in staff in May 2020 would not be sufficient to satisfy its anticipated operating and other funding requirements for the twelve months following the filing of AgeXs Quarterly Report on Form 10-Q for the three months ended March 31, 2020. These factors raise substantial doubt regarding the ability of AgeX to continue as a going concern.

First Quarter 2020 Operating Results

Revenues: Total Revenues for the first quarter of 2020 were $515,000 as compared with $388,000 for the first quarter of 2019. AgeX revenue is primarily generated from subscription and advertising revenues from the GeneCards online database through its subsidiary LifeMap Sciences, Inc. Revenues in 2020 also included approximately $86,000 of allowable expenses under its research grant from the NIH as compared with $15,000 in the same period in 2019.

Operating expenses: Operating expenses reported for the three months ended March 31, 2020 were $3.7 million as compared to $3.4 million for the same period in 2019. On an as-adjusted basis, operating expenses for the three months ended March 31, 2020 were $3.2 million as compared to $2.8 million for the same period in 2019.

The reconciliation between GAAP and non-GAAP operating expenses is provided in the financial tables included with this earnings release.

Research and development expenses increased by $0.3 million to $1.6 million during the three months ended March 31, 2020 from $1.3 million during the same period in 2019. The increase was primarily attributable to an increase of $0.2 million in scientific consultants, $0.2 million in laboratory facilities and equipment related expenses and maintenance, $0.1 million in personnel related expenses allocable to research and development, and $0.1 million in depreciation and amortization of laboratory equipment and improvements. These increases were offset to some extent by a decrease of $0.3 million in shared services from Lineage Cell Therapeutics, Inc. (Lineage) with the termination of the Shared Facilities and Services Agreement on September 30, 2019.

General and administrative expenses for the three months ended March 31, 2020 remained consistent with the same period in 2019 of $2.1 million despite bearing the full lease and facilities related costs since April 2019, and an increase in head count with the employment of AgeXs own finance team since October 1, 2019. These increases were offset by a decrease in shared facilities and services fees from Lineage following the termination of the Shared Facilities and Services Agreement on September 30, 2019.

About AgeX Therapeutics

AgeX Therapeutics, Inc. (NYSE American: AGE) is focused on developing and commercializing innovative therapeutics for human aging. Its PureStem and UniverCyte manufacturing and immunotolerance technologies are designed to work together to generate highly defined, universal, allogeneic, off-the-shelf pluripotent stem cell-derived young cells of any type for application in a variety of diseases with a high unmet medical need. AgeX has two preclinical cell therapy programs: AGEX-VASC1 (vascular progenitor cells) for tissue ischemia and AGEX-BAT1 (brown fat cells) for Type II diabetes. AgeXs revolutionary longevity platform induced Tissue Regeneration (iTR) aims to unlock cellular immortality and regenerative capacity to reverse age-related changes within tissues. AGEX-iTR1547 is an iTR-based formulation in preclinical development. HyStem is AgeXs delivery technology to stably engraft PureStem cell therapies in the body. AgeXs core product pipeline is intended to extend human healthspan. AgeX is seeking opportunities to establish licensing and collaboration arrangements around its broad IP estate and proprietary technology platforms and therapy product candidates.

For more information, please visit http://www.agexinc.com or connect with the company on Twitter, LinkedIn, Facebook, and YouTube.

Forward-Looking Statements

Certain statements contained in this release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not historical fact including, but not limited to statements that contain words such as will, believes, plans, anticipates, expects, estimates should also be considered forward-looking statements. Forward-looking statements involve risks and uncertainties. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the business of AgeX Therapeutics, Inc. and its subsidiaries, particularly those mentioned in the cautionary statements found in more detail in the Risk Factors section of AgeXs most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q filed with the Securities and Exchange Commissions (copies of which may be obtained at http://www.sec.gov). Subsequent events and developments may cause these forward-looking statements to change. AgeX specifically disclaims any obligation or intention to update or revise these forward-looking statements as a result of changed events or circumstances that occur after the date of this release, except as required by applicable law.

AGEX THERAPEUTICS, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED BALANCE SHEETS

(IN THOUSANDS, EXCEPT PAR VALUE AMOUNTS)

March 31,

2020

December 31,

2019

(Unaudited)

ASSETS

CURRENT ASSETS

Cash and cash equivalents

$

468

$

2,352

Accounts and grants receivable, net

366

363

Prepaid expenses and other current assets

1,238

1,339

Total current assets

2,072

4,054

See more here:
AgeX Therapeutics Reports First Quarter 2020 Financial Results and Provides Business Update - Business Wire

Human Embryonic Stem Cells (HESC) Market Growth by Top Companies, Trends by Types and Application, Forecast to 2026 – Cole of Duty

Vitrolife

Moreover, the Human Embryonic Stem Cells (HESC) report offers a detailed analysis of the competitive landscape in terms of regions and the major service providers are also highlighted along with attributes of the market overview, business strategies, financials, developments pertaining as well as the product portfolio of the Human Embryonic Stem Cells (HESC) market. Likewise, this report comprises significant data about market segmentation on the basis of type, application, and regional landscape. The Human Embryonic Stem Cells (HESC) market report also provides a brief analysis of the market opportunities and challenges faced by the leading service provides. This report is specially designed to know accurate market insights and market status.

By Regions:

* North America (The US, Canada, and Mexico)

* Europe (Germany, France, the UK, and Rest of the World)

* Asia Pacific (China, Japan, India, and Rest of Asia Pacific)

* Latin America (Brazil and Rest of Latin America.)

* Middle East & Africa (Saudi Arabia, the UAE, , South Africa, and Rest of Middle East & Africa)

To get Incredible Discounts on this Premium Report, Click Here @ https://www.marketresearchintellect.com/ask-for-discount/?rid=218035&utm_source=NYH&utm_medium=888

Table of Content

1 Introduction of Human Embryonic Stem Cells (HESC) Market

1.1 Overview of the Market1.2 Scope of Report1.3 Assumptions

2 Executive Summary

3 Research Methodology

3.1 Data Mining3.2 Validation3.3 Primary Interviews3.4 List of Data Sources

4 Human Embryonic Stem Cells (HESC) Market Outlook

4.1 Overview4.2 Market Dynamics4.2.1 Drivers4.2.2 Restraints4.2.3 Opportunities4.3 Porters Five Force Model4.4 Value Chain Analysis

5 Human Embryonic Stem Cells (HESC) Market, By Deployment Model

5.1 Overview

6 Human Embryonic Stem Cells (HESC) Market, By Solution

6.1 Overview

7 Human Embryonic Stem Cells (HESC) Market, By Vertical

7.1 Overview

8 Human Embryonic Stem Cells (HESC) Market, By Geography

8.1 Overview8.2 North America8.2.1 U.S.8.2.2 Canada8.2.3 Mexico8.3 Europe8.3.1 Germany8.3.2 U.K.8.3.3 France8.3.4 Rest of Europe8.4 Asia Pacific8.4.1 China8.4.2 Japan8.4.3 India8.4.4 Rest of Asia Pacific8.5 Rest of the World8.5.1 Latin America8.5.2 Middle East

9 Human Embryonic Stem Cells (HESC) Market Competitive Landscape

9.1 Overview9.2 Company Market Ranking9.3 Key Development Strategies

10 Company Profiles

10.1.1 Overview10.1.2 Financial Performance10.1.3 Product Outlook10.1.4 Key Developments

11 Appendix

11.1 Related Research

Get Complete Report

@ https://www.marketresearchintellect.com/need-customization/?rid=218035&utm_source=NYH&utm_medium=888

About Us:

Market Research Intellect provides syndicated and customized research reports to clients from various industries and organizations with the aim of delivering functional expertise. We provide reports for all industries including Energy, Technology, Manufacturing and Construction, Chemicals and Materials, Food and Beverage and more. These reports deliver an in-depth study of the market with industry analysis, market value for regions and countries and trends that are pertinent to the industry.

Contact Us:

Mr. Steven Fernandes

Market Research Intellect

New Jersey ( USA )

Tel: +1-650-781-4080

Tags: Human Embryonic Stem Cells (HESC) Market Size, Human Embryonic Stem Cells (HESC) Market Trends, Human Embryonic Stem Cells (HESC) Market Growth, Human Embryonic Stem Cells (HESC) Market Forecast, Human Embryonic Stem Cells (HESC) Market Analysis Sarkari result, Government Jobs, Sarkari naukri, NMK, Majhi Naukri,

Our Trending Reports

Conductive Inks Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

Industrial Safety Footwear Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

Here is the original post:
Human Embryonic Stem Cells (HESC) Market Growth by Top Companies, Trends by Types and Application, Forecast to 2026 - Cole of Duty

The Cell Therapy Industry to 2028: Global Market & Technology Analysis, Company Profiles of 309 Players (170 Involved in Stem Cells) -…

DUBLIN--(BUSINESS WIRE)--The "Cell Therapy - Technologies, Markets and Companies" report from Jain PharmaBiotech has been added to ResearchAndMarkets.com's offering.

The cell-based markets was analyzed for 2018, and projected to 2028. The markets are analyzed according to therapeutic categories, technologies and geographical areas. The largest expansion will be in diseases of the central nervous system, cancer and cardiovascular disorders. Skin and soft tissue repair as well as diabetes mellitus will be other major markets.

The number of companies involved in cell therapy has increased remarkably during the past few years. More than 500 companies have been identified to be involved in cell therapy and 309 of these are profiled in part II of the report along with tabulation of 302 alliances. Of these companies, 170 are involved in stem cells.

Profiles of 72 academic institutions in the US involved in cell therapy are also included in part II along with their commercial collaborations. The text is supplemented with 67 Tables and 25 Figures. The bibliography contains 1,200 selected references, which are cited in the text.

This report contains information on the following:

The report describes and evaluates cell therapy technologies and methods, which have already started to play an important role in the practice of medicine. Hematopoietic stem cell transplantation is replacing the old fashioned bone marrow transplants. Role of cells in drug discovery is also described. Cell therapy is bound to become a part of medical practice.

Stem cells are discussed in detail in one chapter. Some light is thrown on the current controversy of embryonic sources of stem cells and comparison with adult sources. Other sources of stem cells such as the placenta, cord blood and fat removed by liposuction are also discussed. Stem cells can also be genetically modified prior to transplantation.

Cell therapy technologies overlap with those of gene therapy, cancer vaccines, drug delivery, tissue engineering and regenerative medicine. Pharmaceutical applications of stem cells including those in drug discovery are also described. Various types of cells used, methods of preparation and culture, encapsulation and genetic engineering of cells are discussed. Sources of cells, both human and animal (xenotransplantation) are discussed. Methods of delivery of cell therapy range from injections to surgical implantation using special devices.

Cell therapy has applications in a large number of disorders. The most important are diseases of the nervous system and cancer which are the topics for separate chapters. Other applications include cardiac disorders (myocardial infarction and heart failure), diabetes mellitus, diseases of bones and joints, genetic disorders, and wounds of the skin and soft tissues.

Regulatory and ethical issues involving cell therapy are important and are discussed. Current political debate on the use of stem cells from embryonic sources (hESCs) is also presented. Safety is an essential consideration of any new therapy and regulations for cell therapy are those for biological preparations.

Key Topics Covered

Part I: Technologies, Ethics & Regulations

Executive Summary

1. Introduction to Cell Therapy

2. Cell Therapy Technologies

3. Stem Cells

4. Clinical Applications of Cell Therapy

5. Cell Therapy for Cardiovascular Disorders

6. Cell Therapy for Cancer

7. Cell Therapy for Neurological Disorders

8. Ethical, Legal and Political Aspects of Cell therapy

9. Safety and Regulatory Aspects of Cell Therapy

Part II: Markets, Companies & Academic Institutions

10. Markets and Future Prospects for Cell Therapy

11. Companies Involved in Cell Therapy

12. Academic Institutions

13. References

For more information about this report visit https://www.researchandmarkets.com/r/7h12ne

Here is the original post:
The Cell Therapy Industry to 2028: Global Market & Technology Analysis, Company Profiles of 309 Players (170 Involved in Stem Cells) -...

2025 Projections: Cell Freezing Media for Cell Therapy Market Report by Type, Application and Regional Outlook – AlgosOnline

The ' Cell Freezing Media for Cell Therapy market' report Added by Market Study Report, LLC, enumerates information about the industry in terms of market share, market size, revenue forecasts, and regional outlook. The report further illustrates competitive insights of key players in the business vertical followed by an overview of their diverse portfolios and growth strategies.

The new research report on the Cell Freezing Media for Cell Therapy market provides a comprehensive analysis of the business vertical and comprises of crucial information pertaining to the industry such as profits estimation, periodic deliverables, market size, market share, current revenue, and market tendencies.

Request a sample Report of Cell Freezing Media for Cell Therapy Market at:https://www.marketstudyreport.com/request-a-sample/2547285?utm_source=algosonline.com&utm_medium=TS

A brief summary of the performance analysis of the Cell Freezing Media for Cell Therapy market has been given in the report. Moreover, the report includes pivotal insights such as growth rate expected during the forecast period and key aspects affecting the market size. The Cell Freezing Media for Cell Therapy market report also elaborates on growth opportunities along with hindering factors associated with the industry vertical.

Main pointers highlighted in the Cell Freezing Media for Cell Therapy market report:

Unveiling the geographical landscape of the Cell Freezing Media for Cell Therapy market:

Cell Freezing Media for Cell Therapy Market Segmentation:

A gist of the details presented in the Cell Freezing Media for Cell Therapy market report:

A complete summary of the Cell Freezing Media for Cell Therapy market with regards to the product and application spectrum:

Product landscape:

Product types: With FBS and Without FBS

Key insights presented in the report:

Ask for Discount on Cell Freezing Media for Cell Therapy Market Report at:https://www.marketstudyreport.com/check-for-discount/2547285?utm_source=algosonline.com&utm_medium=TS

Application landscape:

Application segmentation: Human Embryonic Stem Cells, CAR-T Cell Therapy, Neural Stem Cell Therapy, Mesenchymal Stem Cell Therapy, Hematopoietic Stem Cell Transplantation and Other

Specifics provided in the report:

Other major pointers included in the report:

Some details about the competitive landscape of the Cell Freezing Media for Cell Therapy market include:

Vendor base of the industry: BioLife Solutions, Thermo Fisher Scientific, GE Healthcare, Zenoaq, Merck, Akron Biotechnology, WAK-Chemie Medical and Biological Industries

Competitive landscape parameters mentioned in the report include:

For More Details On this Report: https://www.marketstudyreport.com/reports/global-cell-freezing-media-for-cell-therapy-market-growth-2020-2025

Some of the Major Highlights of TOC covers:

Development Trend of Analysis of Cell Freezing Media for Cell Therapy Market

Marketing Channel

Market Dynamics

Methodology/Research Approach

Related Reports:

2. Global Alginate Wound Dressing Market Growth (Status and Outlook) 2020-2025Alginate Wound Dressing Market report characterize imperative Portion and contenders of the market regarding market estimate, volume, esteem. This report likewise covers every one of the locales and nations of the world, which demonstrates a territorial improvement status, it additionally incorporates Business Profile, Introduction, Revenue and so on.Read More: https://www.marketstudyreport.com/reports/global-alginate-wound-dressing-market-growth-status-and-outlook-2020-2025

Read More Reports On: https://www.marketwatch.com/press-release/x-ray-non-destructive-testing-ndt-market-analysis-by-major-companies-size-segmentation-market-dynamics-size-industry-status-and-outlook-to-2025-2020-03-28

Contact Us:Corporate Sales,Market Study Report LLCPhone: 1-302-273-0910Toll Free: 1-866-764-2150 Email: [emailprotected]

More here:
2025 Projections: Cell Freezing Media for Cell Therapy Market Report by Type, Application and Regional Outlook - AlgosOnline

Tolero Pharmaceuticals Announces Expansion of the Zella 102 Study in Patients with Intermediate and High-Risk Myelodysplastic Syndromes (MDS) – The…

SALT LAKE CITY, Utah, May 14, 2020 /PRNewswire/ --Tolero Pharmaceuticals, Inc., a clinical-stage company focused on developing novel therapeutics for hematological and oncological diseases, today announced that the first patient has been dosed with a one-hour dosing schedule for investigational agent alvocidib, a potent CDK9 inhibitor, administered in sequence after azacitidine, in the expansion of the Phase 1b/2 Zella 102 study in patients with myelodysplastic syndromes (MDS).

The Zella 102 study is being conducted in patients with previously untreated MDS and patients with MDS who have received fewer than six cycles of treatment with a hypomethylating agent. The initial study design was to evaluate the safety and efficacy of alvocidib using a 30-minute bolus followed by a four-hour intravenous infusion (IVI), in combination with decitabine. An amendment was made to the study design to include treatment with azacitidine, in sequence before a one-hour infusion of alvocidib.

"We are pleased that this study now includes both standard of care hypomethylating agents for patients with myelodysplastic syndromes. In addition, the expansion of this study offers an alternative alvocidib dosing schedule, which reduces the amount of time patients spend in infusion," said David J. Bearss, Ph.D., Chief Executive Officer, Tolero Pharmaceuticals, and Chief Scientific Officer and Global Head of Research, Global Oncology. "Preclinical research suggests that treatment with hypomethylating agents may sensitize MDS blast cells to suppression of MCL-1 through alvocidib. We look forward to building our understanding of the potential role of alvocidib in this patient population."

MDS is a form of cancer that can occur when cells in the bone marrow are abnormal and create defective blood cells, which often die earlier than normal cells. In one of three patients, MDS can progress into AML, a rapidly growing cancer of bone marrow cells.1

About the Zella 102 Study

The Zella 102 study is an open-label, dose-escalation Phase 1b/2 study evaluating the safety and efficacy of alvocidib, when administered in sequence after eitherdecitabine or azacitidine, in patients with previously untreated MDS and patients with MDS who have received fewer than six cycles of treatment with hypomethylating agents. The primary objective of the Phase 1b portion of the study is to determine the maximum tolerated dose and recommended Phase 2 dose of alvocidib, when administered in these regimens. Secondary objectives are to determinethe complete response rate and if treatment with alvocidib, administered in sequence after decitabine or azacitidine,results in improvements in transfusion dependence and/or hemoglobin level.

The primary objective of the Phase 2 portion of the study will be to determine the objective response rate of alvocidib, when administered to untreated patients with de novo or secondary MDS in sequence after a hypomethylating agent, using revised International Working Group (IWG) criteria.

The trial is being conducted at sites in the United States. Additional information on this trial, including comprehensive inclusion and exclusion criteria, can be accessed at http://www.ClinicalTrials.gov (NCT03593915).

About Alvocidib

Alvocidib is an investigational small molecule inhibitor of cyclin-dependent kinase 9 (CDK9) currently being evaluated in the Phase 2 studies Zella 202, in patients with acute myeloid leukemia (AML) who have either relapsed from or are refractory to venetoclax in combination with decitabineor azacitidine(NCT03969420)and Zella 201, in patients with relapsed or refractory MCL-1 dependent AML, in combination with cytarabine and mitoxantrone(NCT02520011). Alvocidib is also being evaluated in Zella 101, a Phase 1 clinical study evaluating the maximum tolerated dose, safety and clinical activity of alvocidib in combination with cytarabine and daunorubicin (7+3) in newly diagnosed patients with AML(NCT03298984), and Zella 102, a Phase 1b/2 study in patients with myelodysplastic syndromes (MDS) in combination with decitabine or azacitidine(NCT03593915). In addition, alvocidib is being evaluated in a Phase 1 study in patients with relapsed or refractory AML in combination with venetoclax(NCT03441555).

About CDK9 Inhibition and MCL-1

MCL-1 is a member of the apoptosis-regulating BCL-2 family of proteins.2 In normal function, it is essential for early embryonic development and for the survival of multiple cell lineages, including lymphocytes and hematopoietic stem cells.3 MCL-1 inhibits apoptosis and sustains the survival of leukemic blasts, which may lead to relapse or resistance to treatment.2,4 The expression of MCL-1 in leukemic blasts is regulated by cyclin-dependent kinase 9 (CDK9).5,6 Because of the short half-life of MCL-1 (2-4 hours), the effects of targeting upstream pathways are expected to reduce MCL-1 levels rapidly.5 Inhibition of CDK9 has been shown to block MCL-1 transcription, resulting in the rapid downregulation of MCL-1 protein, thus restoring the normal apoptotic regulation.2

About Tolero Pharmaceuticals, Inc.

Tolero Pharmaceuticals is a clinical-stage biopharmaceutical company researching and developing treatments to improve and extend the lives of patients with hematological and oncological diseases. Tolero has a diverse pipeline that targets important biological drivers of blood disorders to treat leukemias, anemia, and solid tumors, as well as targets of drug resistance and transcriptional control.

Tolero Pharmaceuticals is based in the United States and is an indirect, wholly owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd., a pharmaceutical company based in Japan. Tolero works closely with its parent company, Sumitomo Dainippon Pharma, and Boston Biomedical, Inc., also a wholly owned subsidiary, to advance a pipeline of innovative oncology treatments. The organizations apply their expertise and collaborate to achieve a common objective - expediting the discovery, development and commercialization of novel treatment options.

Additional information about the company and its product pipeline can be found atwww.toleropharma.com.

Tolero Pharmaceuticals Forward-Looking Statements

This press release contains "forward-looking statements," as that term is defined in the Private Securities Litigation Reform Act of 1995 regarding the research, development and commercialization of pharmaceutical products. The forward-looking statements in this press release are based on management's assumptions and beliefs in light of information presently available, and involve both known and unknown risks and uncertainties, which could cause actual outcomes to differ materially from current expectations. Any forward-looking statements set forth in this press release speak only as of the date of this press release. We do not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. Information concerning pharmaceuticals (including compounds under development) contained within this material is not intended as advertising or medical advice.

Originally posted here:
Tolero Pharmaceuticals Announces Expansion of the Zella 102 Study in Patients with Intermediate and High-Risk Myelodysplastic Syndromes (MDS) - The...